MULTIPLE MYELOMA

Latest News

Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma
Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma

March 26th 2024

During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.

IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma

March 22nd 2024

Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for Quadruplet Therapy
Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for Quadruplet Therapy

March 20th 2024

Enhancing Outcomes in Myeloma With CAR T Cells and Bispecific Antibodies
Enhancing Outcomes in Myeloma With CAR T Cells and Bispecific Antibodies

March 18th 2024

P-BCMA-ALLO1 Gains FDA Orphan Drug Designation in R/R Multiple Myeloma
P-BCMA-ALLO1 Gains FDA Orphan Drug Designation in R/R Multiple Myeloma

March 18th 2024

Video Series
Video Interviews
Podcasts

More News